NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Trump Says Anthropic No Longer Seen as National Security Threat 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
 - EconoTimes)
NEW YORK, Jan. 29, 2016 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Tetraphase Pharmaceuticals Inc. (“Tetraphase” or the “Company”) (Nasdaq:TTPH) in the United States District Court for the District of Massachusetts on behalf of a class consisting of all persons or entities who purchased Tetraphase securities between March 5, 2015 and September 8, 2015, inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that the Company and certain insiders issued materially false and misleading statements to investors. In particular, the Complaint alleges that the Company made positive statements about the efficacy and potential for its drug Eravacycline to achieve approval by the FDA, despite knowledge that a pivotal portion of its IGNITE2 phase 3 clinical trial for Eravacycline would fail to achieve its primary endpoint of statistical non-inferiority compared to the antibiotic Levofloxacin.
On September 8, 2015, the Company announced that the pivotal portion of its IGNITE2 phase 3 clinical trial of Eravacycline did not achieve its primary endpoint. Following this news, shares of the Company fell from a close of $44.78 on September 8, 2015, to a close of $8.36 per share on September 10, 2015 — a loss of more than 80% in market value.
If you wish to serve as lead plaintiff, you must move the Court no later than March 28, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.
